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I. ABSTRACT  
Brain tumors are the most common childhood solid malignancy, and because of 
remarkable advances in treating many cancers outside of the brain, they have become the leading 
cause of cancer mortality in children. Ependymomas are a class of brain tumors which can be 
further subdivided into three groups based upon their location and genetic features. Of the three 
classes, supratentorial ependymomas are the only subgroup known to be marked by an oncogenic 
driver gene, which consists of a fusion mutation between the C11orf95 and RELA genes. 
C11orf95-RELA positive tumors are the most aggressive and lethal of all ependymomas. With a 
high mortality rate in ependymoma patients and the current lack in effective treatment methods 
for such brain tumors, advancement in treatment targets and mechanisms is necessary to improve 
patient survival. In this study, we assess the use of Notch inhibitors and JQ1 for their 
effectiveness in inhibiting the growth of C11orf95-RELA transformed cells isolated from 
primary brain tumors in mice. We find that both the BET bromodomain inhibitor JQ-1 and the 
FGFR inhibitor AZD4547 inhibit growth of C11orf95-RELA transformed cells and that the BET 
domain inhibitor JQ1 does so with the highest potency.  
 
II. INTRODUCTION  
Ependymomas are a class of brain tumors characterized by neoplasms containing a 
mixture of abnormal glial and endothelial cells. The third most common brain tumor children, 
ependymomas tumors can be divided into several subclassifications based upon their location 
and molecular genetic features[1]. An important subclass of these tumors are supratentorial 
ependymomas (ST-EPN), which develop in the third or lateral ventricles and have been found to 
be significantly correlated with a novel fusion involving the C11orf95 and RELA genes[2]. The 
cellular origin of ST-EPN is an incompletely defined population of neural stem cells (NSCs), 
possibly including radial glial cells (RGCs), intermediate progenitor cells (IPCs), or other related 
NSCs.[3, 4]  The known source of ependymal cells and glial cells in normal development are 
RGCs, thus providing evidence suggesting that RGCs may be the starting cell type of ST-EPN[5].  
Ependymoma, like other cancers, is a genetic disease, with multiple subtypes often 
having distinguishing genetic characteristics. Recently, a C11orf95-RELA fusion mutation has 
been identified as the recurrent genetic alteration driving the ST-EPN subtype of ependymoma[2, 
6, 7, 8, 9, 11]. RELA encodes a well-studied protein known as p65, which plays an integral part in 
the NF-κB pathway, which functions in many cellular processes, including metabolism, 
modulation of immunity, and cell death[10,11]. The function of C11orf95, on the other hand, is 
unknown, although it is believed to encode a protein with zinc finger domains suggesting a role 
in transcriptional regulation[11].  The C11orf95-RELA fusion found in ST-EPN tumors has been 
shown to activate the NF-κB signaling pathway, and to be sufficient to immortalize and 
transform neural stem cells forced to express C11orf95-RELA by viral infection. Taken together, 
two, not mutually exclusive, hypotheses for why the C11orf95-RELA fusion may transform 
some types of neural stem cells into ependymoma have been proposed:  i) inappropriate 
activation of the NF-κB pathway in a population of cells that usually expresses C11orf95 but not 
RELA, and/or ii) altered and dysregulated NF-κB pathway activity because C11orf95 protein 
domains (exons 1-2) become fused to the N-terminus of RELA[8, 10, 11].  
Currently, the primary treatment for ependymoma remains to be surgical resection 
followed by radiotherapy. Although postoperative radiotherapy may induce stabilization and, 
occasionally, regression of residual disease, most incompletely resected tumors ultimately 
progress[7]. Seeing as no chemotherapy regimen has prolonged overall survival in children with 
ependymoma, development of new therapeutic options is needed to increase survival and reduce 
long-term sequels of current treatments.  
Support for the implication of the C11orf95-RELA fusion in both the NF-κB and 
NOTCH signaling pathways as a means of tumorigenesis is well documented[8, 11, 19, 20, 21, 22]. 
Nuclear factor- κB (NF-κB) functions in transcriptional regulation to influence gene expression 
events that impact the immune system as well as cell survival, differentiation, and proliferation. 
The basic scheme of NF- κB signaling consists of a series of positive and negative regulatory 
elements. Activating stimuli trigger activation of IKK, leading to the phosphorylation, 
ubiquitination, and degradation of IκB proteins, which normally function to bind NF- κB and 
prevent its entry into the nucleus[23]. When released from IκB proteins, NF- κB may enter the 
nucleus and promote transcription of genes that function in the production of inflammatory 
mediators, inhibition of apoptosis, and promotion of cell differentiation and division.  The NF- 
κB family of transcription factors consists of five members, one of which is RelA (p65) [23].  
The NOTCH signaling pathway also plays a role in cell survival, differentiation, and 
proliferation. NOTCH genes encode single-pass transmembrane proteins that are activated upon 
binding of their respective ligands[22]. Upon ligand binding, Notch receptors undergo a cascade 
of activating cleavages mediated by a γ-secretase complex. This γ-secretase releases the Notch 
intracellular domain (NCID), enabling it to translocate to the nucleus and associate with 
transcription factors that ultimately lead to transcriptional activation of Notch target genes such 
as HES1, HEY1, and MYC, among many others[22, 23]. 
Given the inability to effectively treat ST-EPN with current standard practices, 
researchers have focused their efforts on evaluating genetic expression profiles and molecular 
pathways. While understanding of the intricate interplay between the various pathways involved 
in tumor initiation, development, and progression still require deeper investigation, potential 
therapeutic targets have been identified, providing key areas of focus for future research. 
Downregulation of the Notch pathway via γ-secretase inhibitors has recently been studied as a 
means of tumor suppression[21, 22, 24]. Puget, et. Al. demonstrated a downregulation of the Notch 
pathway with subsequent reduction in the size, number, and proliferation of neurospheres in a 
2009 trial of ependymoma stem cell cultures[24]. Similarly, Dantas-Barbosa et. Al. found a 
reduction in cell density and viability of ependymoma short-term cell cultures, and tumor growth 
inhibition in advanced-stage glioblastoma xenografts when combined with irradiation[21].  
In targeting the NF-κB pathway, the efficacy of the BET-bromodomain inhibitor JQ-1 as 
a therapeutic target for ST-EPN has also been studied[25]. The bromodomain and extra-terminal 
domain (BET) family comprises four adaptor proteins (Brd2, Brd3, Brd4, and Brdt) that regulate 
transcription by RNA polymerase II. These proteins function by recognizing and binding to 
acetylated lysine residues on histone tails, leading to increased gene expression of the targeted 
genes[26]. BET bromodomain inhibitors can thus serve as effective measures to reduce gene 
expression. Coactivation of the transcriptional activity of NF-κB has been found to be facilitated 
by the BET bromodomain protein Brd4 binding to acetylated RelA.  Specifically, RelA, one of 
the subunits of NF-κB, became acetylated at lysine 310 to facilitate interactions with the 
bromodomains of Brd4[27]. Treatment of the irregular upregulation of NF-κB in ST-EPN may 
thus be possible via the use of BET bromodomain inhibitors. The efficacy of the BET 
bromodomain inhibitor JQ-1 in reducing cell proliferation has been tested in both ependymoma 
and neural stem cell lines[25], but has not yet been tested on cells specifically transformed by the 
C11orf95-RELA oncogene.  
Animal models can be used to test candidate pharmacological therapies against tumor 
cells transformed by defined molecular causes.  Previous attempts to develop ST-EPN animal 
models have utilized viral infection.  We recently developed an additional model of C11orf95-
RELA positive ST-EPN by combining in utero electroporation with a binary piggyBac 
transposon system (PB-IUE).  In this system, a single transfection of neocortical radial glia in the 
fetal brain results in stable transgene expression in the neural lineage of radial glia, including 
neurons, astrocytes, and oligodendrocytes[28].  We have found that introduction of the C11orf95-
RELA oncogene in this system is sufficient to induce tumors resembling ST-EPN in humans, 
and the aggressiveness and lethality of these tumors can be increased by mutating the tumor 
suppressor gene TRP53.  In addition, we have isolated primary cells from these tumors which 
can be propagated in cell cultures over multiple passages.  Both the animal model and primary 
cell cultures of C11orf95-RELA transformed cells can be used to test the effectiveness of 
different molecular and pharmacological therapies.  Specifically, in this thesis project I’ve tested 
notch inhibitors and JQ1 for their effectiveness in inhibiting the growth of C110rf95-RELA 
transformed cells isolated from primary brain tumors in mice. Results indicate that both types of 
blockers inhibit growth of these cells and that the BET domain inhibitor JQ1 does so with the 
highest potency.  The implications of these findings for future in vivo studies and with respect to 
the molecular signaling mechanisms that may underlie uncontrolled tumor growth in ST-EPN 
will be further discussed. 
 
III. METHODS 
Plasmid Construction  
Plasmids were constructed for development of an ST-EPN mouse model. To make 
pPBCAG-FUS1-HA and pPBCAG mCherry, the C11orf95-RELA fusion (termed FUS1) and 
mCherry sequences, respectively, were amplified and replaced the eGFP cassette of a previously 
constructed pPBCAG-eGFP construct. Replacement was achieved using the EcoRI and Not1 
sites of the original plasmid. For construction of pGLAST-PBase, the PBase coding sequence 
was directly inserted downstream of the GLAST promoter, a gift from Fuyi Chen.  
Animals  
 CD1 mice were obtained from Charles River Laboratories, Inc. (Wilmington, MA), and 
maintained at the University of Connecticut vivarium. Animal gestation ages were determined 
and confirmed during surgery. Both male and female embryos were used for surgery, and all 
procedures and experimental approaches were approved by the University of Connecticut 
IACUC.  
 
 
In Utero Electroporation 
 In utero electroporation was performed as previously described[28, 29]. Briefly, rats were 
anesthetized with a mixture of ketamine/xylazine (100/10 mg/kg i.p.). Metacam analgesic was 
administered daily at dosage of 1 mg/kg sub cutaneously at 24 and 48 hours following surgery. 
To visualize the plasmid during electroporation, plasmids were mixed with 2 mg/ml Fast Green 
(Sigma). In all conditions described, pPBCAG-FUS1-HA and the helper plasmid GLAST-PBase 
were used at the final concentration of 1.5 µg/µL, while the fluorescent proteins PBCAG-eGFP 
and PBCAG-mCharry were used at the final concentration of 1.0 µg/µL. Electroporation was 
performed at embryonic day 13 or 15 (E13 or E15). During surgery, the uterine horns were 
exposed and one lateral ventricle of each embryo was pressure injected with 1–2 µl of plasmid 
DNA. Injections were made through the uterine wall and embryonic membranes by inserting a 
pulled glass microelectrodes (Drummond Scientific) into the lateral ventricle and injecting by 
pressure pulses delivered with a Picospritzer II (General Valve). Electroporation was 
accomplished with a BTX 8300 pulse generator (BTX Harvard Apparatus) and BTX 
tweezertrodes. A voltage of 65–75V was used for electroporation. Hippocampal electroporation 
was performed as previously described[30].  
Cell Culture 
Development of ST-EPN Cell Line: A tumor sample from mouse neocortex (P21?) was 
obtained from a mouse model induced with ST-EPN via introduction of the C11orf95-RELA 
fusion by in utero electroporation. The tissue sample was dissociated using mechanical 
disruption followed by trypsin treatment for neural progenitor culture. Cells were grown and 
maintained in DMEM supplemented with 1% penicillin and streptomycin and 10% Fetal Bovine 
Serum. Cells continued to proliferate after 25 passages, demonstrating the development of an 
immortal primary ependymoma cell line.  
Verification of ST-EPN: The C11orf95-RELA fusion was verified using a standard 
immunostaining protocol and microscopy (SP8 confocal microscope) for an HA-tag marking to 
the fusion mutation (PBCAG-FUS1-HA).  
Immunohistochemistry 
Animals were deeply anesthetized with isoflurane and perfused transcardially with 4% 
paraformaldehyde/PBS (4% PFA). Brain samples were post fixed for 24 hours in 4% PFA and 
sectioned at 65 m thickness on a vibratome (Leica VT 1000S). Sections were processed as free-
floating sections. After blocking in PBS containing 5% of normal goat serum (Sigma) and 0.3% 
Triton X-100 (Sigma) for 2 hours at room temperature, tissue sections were incubated with 
primary antibodies overnight at 4 ◦C in the blocking solution. The following primary antibodies 
were used: rabbit anti-HA (1:1000, Invitrogen), and mouse anti-GFP (1:1000, Invitrogen). Tissue 
sections were washed in PBS, incubated with the appropriate secondary antibodies (1:2000 
Alexa Fluor 647 Goat anti-Rabbit, Invitrogen; 1:2000 Alexa Fluor 488 Goat anti-mouse, 
Invitrogen) for 2 hours at room temperature and washed in PBS. In some tissues, nuclei were 
labeled 4-6-diaminodino-2-phenylindole (1:2000, DAPI, Invitrogen). Images were acquired on 
either a Leica TCS SP8 confocal system or Zeiss AXIO Zoom V.16.    
 
 
Cellular Assays 
 5000 cells (from the primary ependymoma cell line) were plated into a 24-well plate in 
500 µL DMEM (1% Pen./Strep., 10% FBS). Drug dilutions were prepared in DMSO. Aliquots 
from the drug-DMSO solutions were added to an appropriate volume of DMEM to generate a 
“Master Solution” in order to reduce pipetting errors. 500 µL of the appropriate solution was 
applied to its respective well 24 hours after cells were seeded. At 48 and 72 hours post-drug 
application, cells were imaged for qualitative analysis using a Leica DMI8 scope. At 72 hours 
post-drug application, a Trypan Blue cell assay was performed. The incubated solutions were 
aspirated and cells were washed once with 500 µL PBS applied carefully to the side of each well. 
After aspiration of the PBS wash, cells were incubated with 100 µL Trypsin for 2 minutes. 
During this time, 10 µL aliquots of Trypan Blue were spotted on a sterile petri dish. 100 µL 
DMEM (1% Pen/Strep., 20% FBS) was then added to each well to resuspend the cells. A 10 µL 
aliquot from a given resuspended well was then mixed with a given 10 µL Trypan blue aliquot. 
The resulting 20 µL solution was mixed by pipetted up and down. From this mixture, 10 µL 
were taken for quantification using an In-CYTO C-Chip disposable hemocytometer. Both the 
total number of cells and the number of blue cells were counted manually using a light 
microscope.  
  
IV. RESULTS 
Transfection with C11orf95-RELA Fusion via IUE is Sufficient to induce ST-EPN in Mice 
Models  
We investigated whether transfection via IUE with the C11orf95-RELA fusion was capable 
of generating ST-EPN neoplasms in mice models. Using an HA tag to the fusion, we see that 
tumors are predominantly comprised of C11orf95-RELA-HA positive cells (Figure 1).  This 
demonstrates that transfection of the fusion into developing mice at E12-14 is sufficient to 
generate ST-EPN tumors. Furthermore, the neoplasms generated in our mice model stain positive 
for GFAP, validating the ST-EPN phenotype as tumors comprised of an abnormal proliferation 
of glial and ependymal cells (not shown).  
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Transfection 
with C11orf95-RELA 
Fusion is Sufficient to 
Induce ST-EPN Tumors 
in Mice. (a) Tumor from 
mouse transfected with 
FUS1 transgene via IUE. 
The neoplasm is 
comprised predominantly 
of HA-tagged FUS1 
transfected cells. A small 
population of GFP-
positive cells visible at 
the top of the neoplasm is 
enlarged in (b), where 
again it is evident that the 
tumor is composed 
predominantly of cells 
expressing the FUS1 
transgene.  
a 
b 
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Validation of C11orf95-RELA Expression in Primary Cell Culture Line 
Using an HA-tag to the C11orf95-RELA fusion, we investigated whether cells of the primary 
ependymoma cell line successfully expressed the fusion construct and demonstrated 
characteristics of ST-EPN. Imaging demonstrates successful expression of the C11orf95-RELA 
fusion, localized to cell nuclei (Figure 2).  
JQ-1, RO4929097, and AZD5447 Exhibit Concentration Responses at 72 hours  
We investigated whether the pharmacological agents JQ-1, RO4929097, and/or 
AZD5447 could limit cell proliferation of the primary Ependymoma cell culture line over the 
course of 72 hours. Qualitatively, it can be seen that JQ-1 and AZD5447 inhibit cell division at 
concentrations greater than 10µM, while RO4929097 has no effect. Although both JQ-1 and 
AZD5447 limit cell proliferation, it appears that JQ-1 serves to limit cell division while 
maintaining normal cell morphology. In contrast, application of AZD5447 generates an irregular 
cell morphology (Figure 3).  
Quantitatively, at concentrations of 30µM, all three drugs demonstrated a reduction in cell 
growth relative to media and DMSO controls. The IC50 of JQ-1 and AZD5447 however, was far 
lower than that of RO4929097, demonstrating a higher efficacy in the former over the latter. 
RO4929097 and AZD5447 both exhibited clear dosage dependence. Both JQ-1 and AZD4557 
reduced cell proliferation at all concentrations tested, although JQ-1 proved the most efficacious; 
significantly limiting cell growth at 1µM (Figure 4). 
Figure 2: Primary Ependymoma Cell Line Demonstrates C11orf95-RELA Positive Tumor Characteristics . The 
HA-tagged C11orf95-RELA fusion is localized to cell nuclei, where it may be acting to upregulate oncogenic 
transcriptional targets . Some endogenous GFP is also present.  
      
 
 
JQ-1 Exhibits Dosage Response in Primary Ependymoma Cell Line 
Identifying JQ-1 as the most effective candidate for further analysis, we then performed a 
full dosage response curve for JQ-1 to better characterize its concentration response. Cell 
proliferation was analyzed at concentrations of 1, 0.3, 0.1, 0.03, and 0.01 µM JQ-1. Qualitative 
analysis demonstrates a clear dosage response curve, with increasing drug concentrations 
eliciting greater inhibition of cell growth in comparison to media and vehicle controls, as 
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Figure 3: Qualitative analysis of cultures at 72 hours. While both JQ-1 and AZD4547 exhibited clear effects at 
concentrations above 10µM, JQ-1 appears to reduce cell proliferation while maintaining normal cell 
morphology. In contrast, AZD4547 appears to limit cell growth in addition to having effects on cell health, as 
seen by the irregular cell morphology and clumping exhibited at 10µM AZD4547. 
Figure 4: Quantitative analysis of cultures at 72 hours. While all three drugs demonstrated clear effects at 
concentrations above 30µM, JQ-1 appears to reduce cell with the most potency; significantly limiting cell 
growth at 1µM. 
expected (Figure 5). Concentrations of 0.1 µM or greater are sufficient to reduce cell 
proliferation; results that match closely with those obtained by Mack et. Al.[25].   
 
 
V. DISCUSSION  
Ependymomas are associated with significant mortality. The 10-year overall survival rate 
is 64% in patients with ependymomas[32]. As such, development of effective and efficient 
treatment methods is crucial to improving patient outcomes. In this study, we assess the use of 
Notch inhibitors and JQ1 for their effectiveness in inhibiting the growth of C11orf95-RELA 
transformed cells isolated from primary brain tumors in mice. Major findings of the study are as 
follows: 1) both the BET bromodomain inhibitor JQ-1 and the FGFR inhibitor AZD4547 inhibit 
growth of C11orf95-RELA transformed cells and 2) the BET domain inhibitor JQ1 does so with 
the highest potency.  
In 2018, Mack et. Al demonstrated that the FGFR blocker AZD4547 and the BET 
bromodomain inhibitor JQ-1 are effective in reducing cell growth in ependymoma cells and a 
neural stem cell line. They did not, however, assess the effectiveness of these drugs in C11orf95-
RELA positive transformed cells. Our results show that both drugs can effectively limit 
proliferation in this cell line, and demonstrate similar IC50 values as to those found by Mack et. 
Al. These results indicate JQ-1 and AZD4547 may be effective treatment methods for limiting 
the growth of ST-EPN tumors.  
Multiple prior studies have found that the NF-κB and Notch singlaing pathways are 
upregulated in ependymoma. The reduction in cell growth elicited by JQ-1 and AZD4547 
application demonstrates that BET bromodomain proteins and Notch signaling may be required 
for EPN growth.  
Seeing as BET bromodomain proteins – particularly Brd4 – play a role in upregulating 
transcription of the NF-κB pathway, specifically via interaction with acetylated RelA, they may 
be required for EPN growth and tumorigenesis. Our results support this hypothesis, as growth is 
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Figure 5: Quantitative analysis of JQ-1 cultures at 72 hours demonstrates clear dosage dependence for JQ-1 on 
primary ependymoma cell culture. JQ-1 exhibits effects on cell proliferation at concentrations above 0.1 µM, 
with an IC50 of approximately 0.1 µM.  
significantly reduced with application of the BET bromodomain inhibitor JQ-1. Further 
biochemical analysis, however, is necessary to gain insight into the mechanism by which JQ-1 
acts to reduce cell proliferation in ependymoma. Additional cell-culture studies utilizing mutated 
RelA constructs to prevent acetylation would help elucidate the interaction of JQ-1 with the NF-
κB pathway in reducing tumor growth. Future work should also involve in vivo analysis of JQ-1 
application on tumorigenesis in our mouse models.  
The composition of the NF-κB dimer is unknown. A better understanding of the makeup 
of the NF-κB components specifically in ST-EPN is needed to develop effective treatment 
methods. Biochemical immunoprecipitation assays to pull down the NF-κB dimer expressed in 
ST-EPN would allow for such identification and aid in the understanding of JQ-1’s application 
for treatment. Additional work analyzing the effects of in vivo overexpression of the different 
NF-κB family members on tumor generation, and whether JQ-1 has any effects in such 
conditions, would also help to further highlight targets driving ST-EPN growth.  
In summary, this study demonstrates the development of the first primary ST-EPN cell 
line that can effectively be used to study ST-EPN tumors. We find that the BET bromodomain 
inhibitor JQ-1 and the FGFR inhibitor AZD4547 limit cell proliferation in this cell line. JQ-1 
specifically limits cell growth at concentrations potentially sufficient for further clinical 
assessment. With the high mortality rate of ST-EPN tumors, development of effective treatment 
methods is crucial to improving patient outcomes. This study highlights two drugs that may 
serve as useful treatment methods with which to treat ST-EPN tumors. With the current lack of a 
chemotherapy regimen that can generate prolonged overall survival in children with 
ependymoma, further development of the use of JQ-1 and/or AZD4547 in our cell line and 
animal models is needed to progress treatment to clinical trials and increase survival in ST-EPN 
patients.  
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